Notice

Shaperon provides timely and transparent updates.

  • Notice
  • News

News

NuGel

Addressing the Root Cause of Atopic Dermatitis
to Restore Skin Health and Reduce Daily Burden

  • Competitiveness

    • First-in-class GPCR19-targeting anti-inflammatory therapy, offering a novel mechanism of action beyond existing PDE4 inhibitors, JAK inhibitors, and steroid-based treatments
    • Simultaneous inhibition of sensitization (Priming) and activation, demonstrating differentiated anti-inflammatory efficacy compared to existing therapies
    • Improvement in key atopic dermatitis clinical endpoints, including EASI and vIGA, with no rebound observed after treatment discontinuation
    • GPCR19-mediated immune modulation minimizes systemic toxicity and adverse effects, supporting long-term use
    • Biomarker-based approach toward personalized treatment tailored to individual patient characteristics
  • Market Outlook

    • Approximately 170 million patients worldwide with atopic dermatitis (Prevalence: ~10% in children, ~3% in adults)
    • Global market size projected at USD 13 billion by 2025, with a CAGR of 16.4%, and expected to reach USD 33 billion by 2030
    • Limitations and adverse effects of existing PDE4 and JAK inhibitors are driving demand for new therapeutic options
  • Unmet Need

    • Lack of safe and effective long-term topical therapies for patients with mild to moderate atopic dermatitis
    • NuGel is positioned as a new standard-of-care candidate addressing this unmet need
  • Development Status

    • Phase 2a clinical trial completed in Korea, demonstrating improvement in EASI and vIGA scores as well as safety
    • Phase 2b clinical trial approved by the U.S. FDA (177 patients, 12-week treatment period) - ongoing
    • Global Phase 2b trial expected to conclude in 2026, with active out-licensing discussions underway
    • Preparation underway for commercialization as a prescription topical therapy
  • EASI*Eczema Area and Severity Index, a composite score evaluating the extent and severity of atopic dermatitis
  • EASI-50*≥50% improvement in EASI score from baseline
  • vIGA*Investigator’s Global Assessment, a 0-4 scale evaluating overall disease severity

Precision Medicine-Based Therapeutic Development:
Identification of Biomarkers Predictive of NuGel Responders

NuGel research data 1
NuGel research data 2

Distinct Efficacy of NuGel Confirmed in Biomarker-Positive Patients

NuGel research data 3
NuGel research data 4

Based on the results of Part 1 of a Phase 2b clinical trial,

NuGel shows great efficacy with atopic dermatitis
patients achieving 100% of EASI-50 in subgroup

NuGel research data 5
NuGel research data 6

NuDifin

Suppressing Inflammation at the Wound Site
to Accelerate Tissue Repair and Regeneration

  • Competitiveness

    • First-in-class GPCR19-targeting anti-inflammatory therapy that fundamentally modulates chronic inflammation and immune imbalance in non-healing wounds
    • Superior tissue penetration, safety, and cost competitiveness compared to growth factor-based therapies such as EGF and PDGF
    • Promotion of wound healing in chronic inflammatory conditions through inhibition of NLRP3 inflammasome activation and NETosis
    • Preclinical data demonstrating improved wound contraction and tissue regeneration compared to EGF
  • Market Outlook

    • The global diabetic population is projected to reach 850 million by 2025 and 1.2 billion by 2050
    • Approximately 19-34% of diabetic patients are expected to experience diabetic foot ulcers (DFUs) during their lifetime, with 9-26 million new cases annually
    • High rates of amputation and mortality associated with treatment failure are driving demand for safe and effective next-generation therapies
    • Limitations of growth factor therapies (low clinical success rates and high costs) are creating opportunities for inflammation-modulating wound therapeutics
  • Unmet Need

    • Existing growth factor-based treatments show variable efficacy, limited tissue penetration, high costs, and potential cancer risk
    • Therapeutic options remain limited for infected or recurrent DFUs
    • There is a lack of treatments capable of preventing recurrence through fundamental control of chronic inflammation
    • NuDifin is being developed as a first-in-class inflammation-modulating wound therapy to address these unmet needs
  • Development Status

    • In preclinical studies, NuDifin demonstrated superior wound healing and tissue regeneration efficacy compared to EGF
    • Phase 2 clinical trial entry targeted for 2026-2027
    • Confirmed topical stability, supporting development as a locally applied wound therapy

NuCerin

A Small but Intelligent Molecule
That Reduces Neuroinflammation and Helps Preserve Memory

  • Competitiveness

    • First-in-class GPCR19-targeting oral therapy offering superior convenience and safety compared to antibody-based treatments
    • Dual mechanism of action: Reduction of neuroinflammation + Promotion of amyloid-β (Aβ) clearance
    • No observed risk of ARIA (amyloid-related imaging abnormalities), including cerebral edema, unlike anti-Aβ antibody therapies → Suitable for long-term administration due to favorable safety profile
  • Market Outlook

    • Approximately 55 million patients worldwide with Alzheimer’s disease, projected to exceed 78 million by 2030
    • Antibody-centric markets face challenges due to high costs, injection burden, and safety concerns, creating unmet demand for alternative therapies
    • Rapid growth of next-generation oral and disease-modifying therapies focused on safety and convenience (estimated CAGR ~20%)
    • Increasing demand for long-term, orally administered treatments for early-stage and prodromal patients
  • Unmet Need

    • Existing antibody therapies suffer from high costs, safety risks, and administration inconvenience, limiting accessibility
    • Lack of orally available therapies suitable for long-term use in early-stage and mild cognitive impairment patients
    • Amyloid clearance-focused approaches alone are insufficient, highlighting the need for integrated modulation of neuroinflammation
    • NuCerin is being developed as a first-in-class, neuroinflammation-modulating oral therapy to address these gaps
  • Development Status

    • Phase 1 clinical trial ongoing in Korea (Part A completed, Part B ongoing)
    • Preclinical studies demonstrated: Improved cognitive function, Neuronal regeneration, Reduction of amyloid-β levels
    • Oral formulation with confirmed safety and stability, suitable for long-term administration

Reduction of Brain Amyloid-β Plaques and Neuroinflammation
following NuCerin Administration in an Alzheimer’s Disease Animal Model

NuCerin research data 1

Improvement in cognitive performance was observed
following NuCerin administration in an Alzheimer’s disease animal model.

NuCerin research data 2

NuSepin

Rapidly Suppressing Excessive Systemic Inflammation
to Accelerate Recovery to Daily Life in Critically Ill Patients

  • Competitiveness

    • First-in-class GPCR19-targeting intravenous anti-inflammatory therapy designed to fundamentally suppress hyperinflammatory responses, including cytokine storm
    • Simultaneous blockade of inflammatory initiation and amplification pathways, demonstrating greater efficacy than existing therapies
    • Rapid clinical response confirmed in Phase 2a, with fast onset of action and no severe adverse events observed
    • Broad potential for indication expansion, including: Severe viral pneumonia, Sepsis, COVID-19, CRS (Cytokine Release Syndrome) following immunotherapy
  • Market Outlook

    • Sustained demand for high-risk, hospitalized patient anti-inflammatory therapies, even in the post-COVID-19 era
    • WHO and CDC reports indicate persistently high mortality rates among critically ill patients, highlighting continued treatment gaps
    • Applicability across systemic inflammatory response syndrome (SIRS), pneumonia, and virus-induced hyperinflammation, supporting a market potential exceeding USD 10 billion
    • Repositioning as a rapid-response therapeutic platform for future pandemics and public health emergencies
  • Unmet Need

    • Antiviral therapies alone show limited ability to reduce immune-mediated mortality
    • Continued safety concerns with JAK/IL-6 inhibitors, including increased infection risk
    • Lack of effective treatments for severe COVID-19 and other hyperinflammatory conditions
    • NuSepin is being developed as a next-generation systemic anti-inflammatory therapy applicable across infectious and immune-mediated hyperinflammatory diseases
  • Development Status

    • Selected as a Korea Drug Development Fund (KDDF)-supported project
    • Global Phase 2b clinical trial completed

Superior improvement was observed in the NuSepin plus antiviral combination group compared to placebo.

NuSepin research data 1

NuPulin

Breaking the Vicious Cycle of Inflammation-Driven Pulmonary Fibrosis
to Help Patients Breathe More Comfortably Again

  • Competitiveness

    • First-in-class GPCR19-targeting oral therapy designed to reduce adverse events and improve long-term treatment convenience compared to existing therapies
    • Anti-fibrotic mechanism via inhibition of inflammasome activation, addressing not only disease progression but also promoting tissue recovery
    • Demonstrated efficacy comparable to existing treatments, with improvement in Ashcroft scores and reduced expression of fibrotic marker α-SMA in preclinical models
    • Selective modulation of immune cells, minimizing systemic adverse effects and supporting long-term administration
  • Market Outlook

    • Idiopathic Pulmonary Fibrosis (IPF) shows a 5-year survival rate of approximately 20%, with a global market size estimated at USD 2.5 billion
    • Among currently approved therapies, treatment discontinuation rates due to adverse events remain high (≈18%)
    • Aging populations are driving increasing prevalence and demand for safe, long-term oral therapies
    • Emergence of a new therapeutic market focused on inflammation–fibrosis dual-modulation mechanisms
  • Unmet Need

    • Existing therapies are largely limited to slowing disease progression, with minimal improvement in survival outcomes
    • Long-term treatment adherence is challenging due to gastrointestinal and other adverse effects
    • No approved therapies capable of achieving meaningful functional recovery and quality-of-life improvement
    • NuPulin is being developed as a next-generation oral therapy that simultaneously suppresses inflammation and fibrosis to address these unmet needs
  • Development Status

    • Phase 1 clinical trial ongoing in Korea (Part A completed, Part B ongoing)
    • In preclinical studies, NuPulin demonstrated suppression of pulmonary fibrosis and improvement in lung function (based on the bleomycin-induced fibrosis model)
    • Confirmed oral stability; under development as a once-daily oral formulation
  • Ashcroft Score* A semi-quantitative scale used to assess the severity of pulmonary fibrosis
  • α-SMA (alpha-smooth muscle actin)* A marker associated with myofibroblast activation and fibrosis progression

Reduction of Fibrosis-Related Markers
following NuPulin Treatment in Human Pulmonary Fibroblasts

NuPulin research data 1

Reduction in Histopathological Fibrosis Scores
following NuPulin Administration in an Idiopathic Pulmonary Fibrosis Animal Model

NuPulin research data 2
  • Vehicle A: Control group for comparator treatment
  • Vehicle B: Control group for NuPulin treatment
  • Bleomycin: A pulmonary fibrosis-inducing agent
  • Ashcroft Score: A semi-quantitative scale used to assess the severity of pulmonary fibrosis

Papiliximab

Setting a new standard for leukemia care by combining
enhanced anti-cancer efficacy with a reduced anemia risk.

  • Competitiveness

    • World’s first bispecific NanoMab simultaneously targeting PD-L1 and CD47
    • Maximizes tumor cell elimination by effectively neutralizing immune evasion mechanisms in cancer cells
    • Addresses anemia, the most critical adverse effect associated with conventional CD47 antibody therapies
    • Demonstrated favorable safety profile in non-human primate studies and superior tumor growth inhibition in vivo compared to existing antibodies
    • Small, high-stability nanobody format enables scalable manufacturing and reduced production costs
  • Market Outlook

    • The global bispecific antibody market is projected to grow from USD 18 billion in 2025 to USD 48.5 billion by 2034
    • The global acute myeloid leukemia (AML) market is expected to grow at a CAGR exceeding 10%, reaching approximately USD 10 billion by 2028
    • Despite strong interest, CD47-based immunotherapies have faced commercialization delays due to hematologic toxicities
    • Rapid expansion of the next-generation immuno-oncology market focused on safe immune activation
  • Unmet Need

    • Existing anti-PD-L1 monotherapies show limited response rates and resistance issues
    • Many CD47 antibodies have been discontinued due to severe anemia and hemagglutination-related toxicities
    • Strong demand for safe bispecific or novel-format immunotherapies
    • Papiliximab is positioned as a next-generation bispecific immuno-oncology candidate designed to overcome these limitations
  • Development Status

    • Preclinical development completed
    • In humanized mouse models of AML and lymphoma, Papiliximab demonstrated:
    • Superior tumor growth inhibition compared to comparator groups
    • More than five-fold improvement in overall survival
    • Non-human primate studies confirmed:
    • No red blood cell binding
    • No hemagglutination
    • Favorable pharmacokinetic (PK) stability
    • Strategically positioned as the first clinical entry candidate leveraging Shaperon’s bispecific NanoMab platform

Superior Tumor Growth Inhibition and Extended Survival
following Papiliximab Administration in a Humanized Lymphoma Mouse Model

Papiliximab research data 1
Papiliximab research data 2

Confirming Mitigation of Hemolytic Toxicity Associated with Conventional CD47 Antibodies

Papiliximab research data 3

Preparing

We are currently preparing the detail page.
Thank you.